RIGEL PHARMACEUTICALS,INC. (NASDAQ:RIGL) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May2, 2017, Rigel Pharmaceuticals,Inc. (the Company)
announced certain financial results for the first quarter ended
March31, 2017. A copy of the Companys press release, titled Rigel
Announces First Quarter 2017 Financial Results and Provides
Company Update, is furnished to Item 2.02 as Exhibit99.1 hereto.
Item 5.07. Submission of Matters to a Vote of Security
Holders.
The Companys 2017 Annual Meeting of Stockholders (the Annual
Meeting) was held on May 11, 2017. The following is a brief
description of each matter voted upon at the Annual Meeting, as
well as the number of votes cast for or against each matter and
the number of abstentions and broker non-votes with respect to
each matter. A more complete description of each matter is set
forth in the Companys definitive proxy statement for the Annual
Meeting filed with the Securities and Exchange Commission on
March 29, 2017.
Each of the two nominees for director, to serve until the
Companys 2020 Annual Meeting of Stockholders or until his
respective successor has been elected and qualified, was elected
as follows:
|
Nominee |
|
Shares VotedFor |
|
Shares Withheld |
|
|
Raul R. Rodriguez |
83,753,142 |
360,198 |
|||
|
Walter H. Moos, Ph.D. |
81,710,145 |
2,403,195 |
There were 20,804,479 broker non-votes for this matter.
The Companys stockholders approved the Companys 2011 Equity
Incentive Plan, as amended.
The tabulation of votes on this matter was as follows: shares
voted for: 60,189,483; shares voted against: 23,864,534; shares
abstaining: 59,323; and broker non-votes: 20,804,479.
The Companys stockholders approved the Companys 2000
Non-Employee Directors Plan, as amended.
The tabulation of votes on this matter was as follows: shares
voted for: 60,812,627; shares voted against: 23,242,455; shares
abstaining: 58,258; and broker non-votes: 20,804,479.
The Companys stockholders approved, on an advisory basis, the
compensation of the Companys named executive officers.
The tabulation of votes on this matter was as follows: shares
voted for: 83,476,295; shares voted against: 547,490; shares
abstaining: 89,555; and broker non-votes: 20,804,479.
The Companys stockholders approved, on an advisory basis, the
preferred frequency of stockholder advisory votes on the
compensation of the Companys named executive officers.
The tabulation of votes on this matter was as follows: shares
voted for every year: 74,616,242; shares voted for every two
years: 56,818; shares voted for every three years: 9,383,725;
shares abstaining: 56,555; and broker non-votes: 20,804,479.
The Companys stockholders ratified the selection of Ernst Young
LLP as the independent registered public accounting firm of the
Company for its fiscal year ending December31, 2017.
The tabulation of votes on this matter was as follows: shares
voted for: 101,528,280; shares voted against: 3,269,062; and
shares abstaining: 120,477.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit |
|
Description |
|
99.1 |
Press Release, dated May2, 2017, titled Rigel Announces |
The information in Item 2.02 this report, including the exhibit
hereto, shall not be deemed to be filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section11 and
12(a)(2)of the Securities Act of 1933, as amended. The
information contained in Item 2.02 of this report and in the
accompanying exhibit shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange
Commission made by Rigel Pharmaceuticals,Inc., whether made
before or after the date hereof, regardless of any general
incorporation language in such filing.
About RIGEL PHARMACEUTICALS, INC. (NASDAQ:RIGL)
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company’s clinical programs include clinical studies of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a range of indications. It has completed Phase III clinical trial of fostamatinib in chronic immune thrombocytopenia (ITP). The Company is conducting a Phase II clinical study with fostamatinib in autoimmune hemolytic anemia (AIHA) and a Phase II clinical study for IgA nephropathy (IgAN). In addition, the Company has two oncology product candidates under development. The Company’s product pipeline also includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor indicated for patients with ocular graft-versus-host disease (GvHD). R348 reduces inflammation and limits the damage to the eye tissue caused by the disease. RIGEL PHARMACEUTICALS, INC. (NASDAQ:RIGL) Recent Trading Information
RIGEL PHARMACEUTICALS, INC. (NASDAQ:RIGL) closed its last trading session up +0.07 at 2.68 with 541,865 shares trading hands.
